Ashley E Davis

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Acinetobacter Baumannii

Men Who Have Sex With Men

Top Venues

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics 42 (4) (2024)
Anita J Brogan, Ashley E Davis, Claire E Mellott, Jeremy Fraysse, Aimee A Metzner, Alan K Oglesby
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States. PharmacoEconomics (2024)
Anita J Brogan, Sandra E Talbird, Ashley E Davis, Elizabeth M La, Princy N Kumar
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. PharmacoEconomics 39 (4) (2021)